In support of these findings, a recent proteome profiling study of samples from patients with metastatic melanoma undergoing either tumor infiltrating lymphocyte based or anti-PD1 immunotherapy demonstrated that the fatty acid oxidation pathway was significantly enriched in responder patients. This evidence concerns the gene PDCD1 and neoplasm.